trending Market Intelligence /marketintelligence/en/news-insights/trending/gjgU_7tgenSyRlo0nAmPKQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Chiasma resubmits application for hormonal disorder drug in US

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Chiasma resubmits application for hormonal disorder drug in US

Chiasma Inc. said it resubmitted a new drug application for Mycapssa in the U.S.

The Waltham, Mass.-based biopharmaceutical company is seeking the U.S. Food and Drug Administration's approval to market Mycapssa as a maintenance treatment for adults with acromegaly, a hormonal disorder that causes an increase in the size of bones of the hands, feet and face. Maintenance therapy is an add-on treatment meant to bolster the main therapy.

Chiasma said in a Jan. 10 press release that its application was backed by positive data from a phase 3 trial, dubbed Chiasma Optimal.

The company said it expects a six-month review of the filing and expects a decision by the FDA by mid-year and hopes to bring the product to the market during the fourth quarter of 2020.

Chiasma also expects to report results from an international phase 3 trial of Mycapssa — called Mpowered — to support the drug's approval in the EU.